Business Context and Reporting Period
This Form 8-K Current Report was filed by vTv Therapeutics Inc. on September 14, 2017. The filing addresses a specific regulatory event regarding the company's listing status on the NASDAQ Stock Market.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. However, it discloses the following market-based data as of September 14, 2017:
- Total Market Capitalization: $176.2 million (calculated based on the closing trading price of Class A Common Stock and giving effect to the full exchange of Class B Common Stock and vTv LLC Units).
- Outstanding Class A Common Stock: 9,693,254 shares.
- Outstanding Class B Common Stock: 23,119,246 shares (exchangeable for Class A).
- Market Value of Listed Securities: Exceeded $50 million for 10 consecutive business days.
Material Changes
The primary material change reported is the restoration of compliance with NASDAQ listing requirements. Previously, the company had received notice of non-compliance with NASDAQ Rule 5450(b)(2)(A) regarding the minimum market value of listed securities. The filing confirms that the company has regained compliance, and the matter previously disclosed in a June 30, 2017, Form 8-K has been closed.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of new risks or contingencies. The document is strictly a notification of the resolution of a listing deficiency.
Key Facts for Investor Verification
- Confirm the current trading status of vTv Therapeutics Inc. on the NASDAQ Global Market.
- Verify the current share count and exchange ratio between Class A and Class B common stock.
- Review the June 30, 2017, Form 8-K to understand the initial deficiency notice regarding market value.
- Check subsequent filings for any updates on the company's financial performance, as this report does not contain operational data.